Verapamil therapy for stable exertional angina pectoris.

Clinical and exercise responses to therapy with the calcium-channel blocking agent verapamil were assessed in 26 patients with stable exertional angina pectoris using a double-blind, placebo-controlled, randomized crossover study design. Verapamil, 480 mg daily, reduced the frequency of angina attacks (5.6 +/- 7.3 to 2.2 +/- 3.0 attacks per week, p less than 0.001) and number of nitroglycerin tablets consumed (3.4 +/- 4.9 to 1.2 +/- 2.5 tablets per week, p less than 0.05), and increased exercise duration (6.4 +/- 2.1 to 7.5 to 1.8 minutes, p less than 0.001) (all data are mean +/- standard deviation). These changes were significantly better than those seen with placebo. These beneficial effects of verapamil were related to significant reduction in the heart rate-systolic blood pressure product during submaximal exercise. Adverse effects from verapamil were few and consisted primarily of constipation in 6 patients. A total of 193 patients had been entered in 6 independent clinical trials, which have compared verapamil with placebo for the treatment of stable exertional angina pectoris, using a similar study design. The combined evidence from all these studies indicates that verapamil is a highly effective and safe drug for the treatment of stable effort-related angina pectoris.
AuthorsD A Weiner, M D Klein
JournalThe American journal of cardiology (Am J Cardiol) Vol. 50 Issue 5 Pg. 1153-7 (Nov 1982) ISSN: 0002-9149 [Print] UNITED STATES
PMID6814225 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Verapamil
  • Nitroglycerin
  • Adult
  • Aged
  • Angina Pectoris (drug therapy)
  • Blood Pressure (drug effects)
  • Clinical Trials as Topic
  • Constipation (chemically induced)
  • Double-Blind Method
  • Heart Rate (drug effects)
  • Humans
  • Male
  • Middle Aged
  • Nitroglycerin (therapeutic use)
  • Physical Exertion
  • Random Allocation
  • Verapamil (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: